Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1,616

Immunotherapy can be critical to treatment of different types of cancer, claim research

Washington, Scientists have found a novel immunotherapy that could bolster the effectiveness of cancer treatment, according to a study. Rather than rally T cells against cancer, scientists have used different human immune cells called natural killer (NK) cells as a novel means to fight cancer, according to a study.

The team of scientists at Albert Einstein College of Medicine described findings that could boost the impact of immune-checkpoint therapy, the study said. Findings have been published in The Journal of Clinical Investigation (JCI).

Immune checkpoint inhibitors such as Keytruda and Opdivo work by unleashing the immune system’s T cells to attack tumour cells. Their introduction a decade ago marked a major advance in cancer therapy, but only 10 per cent to 30 per cent of treated patients experience long-term improvement, the study said.

Competition between respiratory viruses may hold off a ‘tripledemic’ this winter

Triple threat. Tripledemic. A viral perfect storm. These frightening phrases have dominated recent headlines as some health officials, clinicians, and scientists forecast that SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) could surge at the same time in Northern Hemisphere locales that have relaxed masking, social distancing, and other COVID-19 precautions.

But a growing body of epidemiological and laboratory evidence offers some reassurance: SARS-CoV-2 and other respiratory viruses often “interfere” with each other. Although waves of each virus may stress emergency rooms and intensive care units, the small clique of researchers who study these viral collisions say there is little chance the trio will peak together and collectively crash hospital systems the way COVID-19 did at the pandemic’s start.

“Flu and other respiratory viruses and SARS-CoV-2 just don’t get along very well together,” says virologist Richard Webby, an influenza researcher at St. Jude Children’s Research Hospital. “It’s unlikely that they will circulate widely at the same time.”

Cell therapy process for heart regeneration may advance treatment of cardiovascular disease

A researcher at the University of Houston College of Pharmacy is reporting an effective protocol for reprogramming human heart cells into specialized cells that conduct electricity throughout the heart to enable rhythmic heartbeat and repair diseased hearts. Bradley McConnell, professor of pharmacology, is the first to demonstrate the process and is reporting it in iScience.

It could be a massive breakthrough.

Currently, there are no treatments for cardiac cell death, the underlying basis of cardiovascular disease (CVD), which remains the leading cause of death globally. By 2035, CVD prevalence is expected to increase to 45.1% (more than 130 million people) in the U.S. while the financial cost is projected to increase by more than $131 million over the next two decades, reaching an astounding $1.1 trillion.

Mayo Clinic Q&A podcast: The latest options for treating epilepsy

Research in the field continues to focus on seizure prevention, prediction and treatment. Dr. Van Gompel predicts that the use of artificial intelligence and machine learning will help neurologists and neurosurgeons continue to move toward better treatment options and outcomes.

“I think we will continue to move more and more toward removing less and less brain,” says Dr. Van Gompel. “And in fact, I do believe in decades, we’ll understand stimulation enough that maybe we’ll never cut out brain again. Maybe we’ll be able to treat that misbehaving brain with electricity or something else. Maybe sometimes it’s drug delivery, directly into the area, that will rehabilitate that area to make it functional cortex again. That’s at least our hope.”

On the Mayo Clinic Q&A podcast, Dr. Van Gompel discusses the latest treatment options for epilepsy and what’s on the horizon in research.

Greg Bear, prize-winning sci-fi author and Comic-Con co-founder, dies at 71

Greg Bear, the affable San Diego native who wrote such highly acclaimed and plausible science fiction novels as “Blood Music,” “Darwin’s Radio” and “Eon” and who helped create San Diego Comic-Con, died Saturday in Seattle. He was 71.

His books included “Blood Music” and “Darwin’s Radio,” which helped establish him as a “hard” sci-writer who created plausible tales with the help of scientists.

I got world’s first double arm transplant — and can finally hug my grandkids

He has surpassed every medical expectation throughout his recovery. Gretarsson can now walk his dog, brush his teeth and give high-fives — as demonstrated when he met Iceland’s president.

“I have feelings in every finger, in the hand,” Gretarsson said recently alongside his wife, Silvia, Friday on “Good Morning Britain.”

Of course, recovery has been a complicated one.

Treatment of SARS-CoV-2-induced pneumonia with NAD+ and NMN in two mouse models

The global COVID-19 epidemic has spread rapidly around the world and caused the death of more than 5 million people. It is urgent to develop effective strategies to treat COVID-19 patients. Here, we revealed that SARS-CoV-2 infection resulted in the dysregulation of genes associated with NAD+ metabolism, immune response, and cell death in mice, similar to that in COVID-19 patients. We therefore investigated the effect of treatment with NAD+ and its intermediate (NMN) and found that the pneumonia phenotypes, including excessive inflammatory cell infiltration, hemolysis, and embolization in SARS-CoV-2-infected lungs were significantly rescued. Cell death was suppressed substantially by NAD+ and NMN supplementation. More strikingly, NMN supplementation can protect 30% of aged mice infected with the lethal mouse-adapted SARS-CoV-2 from death.

A combination of ultrasound and nanobubbles allows cancerous tumors to be destroyed without invasive treatments

A new technology developed at Tel Aviv University makes it possible to destroy cancerous tumors in a targeted manner, via a combination of ultrasound and the injection of nanobubbles into the bloodstream. According to the research team, unlike invasive treatment methods or the injection of microbubbles into the tumor itself, this latest technology enables the destruction of the tumor in a non-invasive manner.

The study was conducted under the leadership of doctoral student Mike Bismuth from the lab of Dr. Tali Ilovitsh at Tel Aviv University’s Department of Biomedical Engineering, in collaboration with Dr. Dov Hershkovitz of the Department of Pathology. Prof. Agata Exner from Case Western Reserve University in Cleveland also participated in the study. The study was published in the journal Nanoscale.

Dr. Tali Ilovitsh says that their “new technology makes it possible, in a relatively simple way, to inject nanobubbles into the bloodstream, which then congregate in the area of the cancerous . After that, using a low-frequency ultrasound, we explode the nanobubbles, and thereby the tumor.”

/* */